Empagliflozin for diabetes mellitus, type 2

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 26 Nov 2018: Trial registered, NCT03753087
  2. 16 Jan 2019: Trial started, NCT03753087

The trials

NCT03554200: EMPA Acute Heart Failure

State
Stopped early
Phase
Phase 2
People
19 taking part
Started
11 Jun 2018
Primary completion
29 Oct 2020
Arms
Empagliflozin
Results
None posted
  1. 11 Jun 2018: Trial started
  2. 13 Jun 2018: Trial registered
  3. 29 Oct 2020: Trial terminated

NCT03753087: Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

State
Completed
Phase
Phase 4
People
70 taking part
Started
16 Jan 2019
Primary completion
16 Dec 2021
Arms
Empagliflozin
Results
None posted
  1. 26 Nov 2018: Trial registered
  2. 16 Jan 2019: Trial started
  3. 10 Jan 2022: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Empagliflozin 10 MG, Empagliflozin 10 MG OD, Empagliflozin 25 MG, Empagliflozin10Mg Tab, Glyxambi component empagliflozin, Jardiance, Trijardy xr component empagliflozin.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.